FIRE-8
Prospective, randomized, open, multicenter Phase II trial to investigate the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment of metastatic colorectal cancer
II
interventionell
National
Trifluridin/Tipiracil (Lonsurf®) , Panitumumab (Vectibix®), Bevacizumab (Avastin®)
Status: In Rekrutierung
Zeitraum
2021
2024
Patienten
153
51
18.03.2024
Klinische Settings
IV
1st line
palliativ
Beteiligte
AIO-Arbeitsgruppen
Sponsor
Charité Universitätsmedizin Berlin
Förderer
Servier, Amgen
Identifier
AIO-KRK/YMO-0519
AIO-KRK/YMO-0519
2019-004223-20
Kontakt
Leitung
Prof. Dr. med. Dominik Modest
Ansprechpartner*in
Dr. rer. nat. Inna Hoyer
Telefon +49 030 450553727
E-Mail inna.hoyer@charite.de